BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 3897803)

  • 21. Herpes simplex infection.
    Fitzherbert JC
    Aust Fam Physician; 1978 Oct; 7(10):1313. PubMed ID: 736842
    [No Abstract]   [Full Text] [Related]  

  • 22. The alpha-herpesviridae in dermatology : Herpes simplex virus types I and II.
    El Hayderi L; Rübben A; Nikkels AF
    Hautarzt; 2017 Dec; 68(Suppl 1):1-5. PubMed ID: 28197698
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prophylactic topical acyclovir for frequent recurrent herpes simplex infection with and without erythema multiforme.
    Fawcett HA; Wansbrough-Jones MH; Clark AE; Leigh IM
    Br Med J (Clin Res Ed); 1983 Sep; 287(6395):798-9. PubMed ID: 6412833
    [No Abstract]   [Full Text] [Related]  

  • 24. Double-blind controlled trial of topical acyclovir in genital herpes simplex virus infections.
    Corey L; Benedetti JK; Critchlow CW; Remington MR; Winter CA; Fahnlander AL; Smith K; Salter DL; Keeney RE; Davis LG; Hintz MA; Connor JD; Holmes KK
    Am J Med; 1982 Jul; 73(1A):326-34. PubMed ID: 7048919
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Management of non-genital herpes simplex virus infections in immunocompetent patients.
    Leigh IM
    Am J Med; 1988 Aug; 85(2A):34-8. PubMed ID: 3044090
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Possibilities and limits of chemotherapy of diseases caused by herpes simplex and varicella-zoster virus].
    Wassilew SW
    Hautarzt; 1983 Jan; 34(1):1-5. PubMed ID: 6841073
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nongenital herpes simplex virus.
    Usatine RP; Tinitigan R
    Am Fam Physician; 2010 Nov; 82(9):1075-82. PubMed ID: 21121552
    [TBL] [Abstract][Full Text] [Related]  

  • 28. New treatment for herpes simplex virus type 2 [ultrasound and zinc, urea, and tannic acid ointment]. Part I--Male patients.
    Fahim M; Brawner T; Millikan L; Nickell M; Hall D
    J Med; 1978; 9(3):245-64. PubMed ID: 283170
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Penciclovir cream--improved topical treatment for herpes simplex infections.
    Schmid-Wendtner MH; Korting HC
    Skin Pharmacol Physiol; 2004; 17(5):214-8. PubMed ID: 15452407
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Acyclovir prophylaxis to prevent herpes simplex virus recurrence at delivery: a systematic review.
    Sheffield JS; Hollier LM; Hill JB; Stuart GS; Wendel GD
    Obstet Gynecol; 2003 Dec; 102(6):1396-403. PubMed ID: 14662233
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thymine arabinoside (Ara-T) topical and iontophoretic application for herpes simplex virus type 1 and type 2 skin infections in hairless mice.
    Hill JM; Wiggins CA; Kwon BS; Gentry GA; Gangarosa LP
    Methods Find Exp Clin Pharmacol; 1984 Jan; 6(1):17-20. PubMed ID: 6717166
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical course and diagnosis of genital herpes simplex virus infection and evaluation of topical surfactant therapy.
    Vontver LA; Reeves WC; Rattray M; Corey L; Remington MA; Tolentino E; Schweid A; Holmes KK
    Am J Obstet Gynecol; 1979 Mar; 133(5):548-54. PubMed ID: 375733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Treatment of acyclovir-resistant herpetic ulceration with topical foscarnet and antiviral sensitivity analysis.
    Pechère M; Wunderli W; Trellu-Toutous L; Harms M; Saura JH; Krischer J
    Dermatology; 1998; 197(3):278-80. PubMed ID: 9812037
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Herpes simplex virus: benefit versus risk factors in immunization.
    zur Hausen H
    Dev Biol Stand; 1979; 43():373-9. PubMed ID: 230113
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Acyclovir. An updated review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy.
    O'Brien JJ; Campoli-Richards DM
    Drugs; 1989 Mar; 37(3):233-309. PubMed ID: 2653790
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Value of the dorsal cutaneous guinea pig model in selecting topical antiviral formulations for the treatment of recurrent herpes simplex type 1 disease.
    Poli G; Dall'Ara P; Binda S; Santus G; Poli A; Cocilovo A; Ponti W
    Arzneimittelforschung; 2001; 51(5):433-8. PubMed ID: 11413746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucocutaneous herpes simplex virus infections in immunocompromised patients. A model for evaluation of topical antiviral agents.
    Whitley R; Barton N; Collins E; Whelchel J; Diethelm AG
    Am J Med; 1982 Jul; 73(1A):236-40. PubMed ID: 7048915
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Multiple herpetic whitlow lesions in a 4-year-old girl: case report and review of the literature.
    Szinnai G; Schaad UB; Heininger U
    Eur J Pediatr; 2001 Sep; 160(9):528-33. PubMed ID: 11585074
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Limited efficacy of inhibitors of herpes simplex virus DNA synthesis in murine models of recrudescent disease.
    Kristofferson A; Ericson AC; Sohl-Akerlund A; Datema R
    J Gen Virol; 1988 Jun; 69 ( Pt 6)():1157-66. PubMed ID: 2838569
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Herpes simplex].
    Välimaa H; Seppänen M; Hukkanen V
    Duodecim; 2013; 129(1):31-40. PubMed ID: 23431880
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.